Development of inhibitors of receptor protein tyrosine phosphatase ß/ζ (PTPRZ1) as candidates for CNS disorders.
Eur J Med Chem
; 144: 318-329, 2018 Jan 20.
Article
in En
| MEDLINE
| ID: mdl-29275231
ABSTRACT
A new series of blood-brain barrier permeable molecules designed to mimic the activity of Pleiotrophin in the CNS has been designed and synthesized. These compounds exert their action by interacting with the intracellular domain PD1 of the Protein Tyrosine-Phosphatase Receptor Z1 (PTPRZ1), and inhibiting its tyrosine phosphatase activity. The most potent compounds 10a and 12b (IC50 = 0,1 µM) significantly increase the phosphorylation of key tyrosine residues of PTPRZ1 substrates involved in neuronal survival and differentiation, and display protective effects against amphetamine-induced toxicity. Docking and molecular dynamics experiments have been used to analyze the binding mode and to explain the observed selectivity against PTP1B. An In vivo experiment has demonstrated that 10a can cross the BBB, thus promoting the possibility of moving forward these candidates for the development of drugs for the treatment of CNS disorders, such as drug addiction and neurodegenerative diseases.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carrier Proteins
/
Central Nervous System Diseases
/
Anti-Inflammatory Agents, Non-Steroidal
/
Cytokines
/
Enzyme Inhibitors
/
Receptor-Like Protein Tyrosine Phosphatases, Class 5
Limits:
Animals
/
Humans
Language:
En
Journal:
Eur J Med Chem
Year:
2018
Document type:
Article
Affiliation country:
España